Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$130.86 - $143.19 $15,834 - $17,325
121 Added 4.73%
2,679 $368,000
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $564,632 - $622,394
-4,330 Reduced 62.86%
2,558 $352,000
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $101,296 - $126,785
955 Added 16.1%
6,888 $907,000
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $4,386 - $5,138
49 Added 0.83%
5,933 $559,000
Q1 2023

May 15, 2023

SELL
$94.11 - $123.02 $15,622 - $20,421
-166 Reduced 2.74%
5,884 $595,000
Q3 2022

Nov 02, 2022

SELL
$92.03 - $107.81 $7,730 - $9,056
-84 Reduced 1.37%
6,050 $643,000
Q2 2022

Aug 03, 2022

BUY
$75.79 - $100.07 $3,562 - $4,703
47 Added 0.77%
6,134 $598,000
Q1 2022

May 04, 2022

BUY
$72.45 - $94.81 $40,644 - $53,188
561 Added 10.15%
6,087 $571,000
Q4 2021

Mar 07, 2022

SELL
$79.65 - $106.22 $61,330 - $81,789
-770 Reduced 12.23%
5,526 $471,000
Q3 2021

Oct 27, 2021

BUY
$86.18 - $99.03 $45,158 - $51,891
524 Added 9.08%
6,296 $604,000
Q2 2021

Aug 12, 2021

BUY
$89.43 - $102.27 $10,373 - $11,863
116 Added 2.05%
5,772 $562,000
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $495,295 - $675,326
5,656 New
5,656 $550,000
Q4 2020

Feb 10, 2021

SELL
$86.91 - $108.33 $485,218 - $604,806
-5,583 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $26,059 - $36,625
271 Added 5.1%
5,583 $537,000
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $398,984 - $604,293
5,312 New
5,312 $460,000
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $463,512 - $633,163
-5,340 Closed
0 $0
Q3 2019

Oct 18, 2019

BUY
$83.82 - $101.5 $70,408 - $85,260
840 Added 18.67%
5,340 $481,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $444,960 - $566,325
4,500 New
4,500 $553,000
Q3 2017

Nov 08, 2017

SELL
$47.97 - $61.28 $215,865 - $275,760
-4,500 Closed
0 $0
Q2 2017

Aug 10, 2017

BUY
N/A
4,500
4,500 $207,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Stephens Inc Portfolio

Follow Stephens Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.